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Abbreviations 
 
AIFCT, AIF forms in CT complex with NAD+; 
AIFOX, AIF forms harboring oxidized FAD; 
CHCHD4, coiled-coil-helix-coiled-coil-helix domain-containing protein 4; 
CT, charge transfer; 
DCIP, 2,6-dichlorophenolindophenol; 
FADH-, anionic dihydroquinone form of FAD; 
OXPHOS, oxidative phosphorylation. 
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Abstract 
The apoptosis-inducing factor (AIF) is a FAD-containing protein playing critical roles 
in caspase-independent apoptosis and mitochondrial respiratory chain biogenesis and 
maintenance. While its lethal role is well known, the details of its mitochondrial 
function remain elusive. So far, nineteen allelic variants of AIF have been associated 
to human diseases, mainly affecting the nervous system. A strict correlation is 
emerging between the degree of impairment of its ability to stabilize the charge-
transfer (CT) complex between FAD and NAD+ and the severity of the resulting 
pathology. Recently, we demonstrated that the G307E replacement in murine AIF 
(equivalent to the pathogenic G308E in the human protein) dramatically decreases the 
rate of CT complex formation through the destabilization of the flavoprotein 
interaction with NAD(H). To provide further insights into the structural bases of its 
altered functional properties, here we report the first crystal structure of an AIF 
pathogenic mutant variant in complex with NAD+ (murine AIF-G307ECT) in 
comparison with its oxidized form. With respect to wild type AIF, the mutation leads 
to an altered positioning of NAD+ adenylate moiety, which slows down CT complex 
formation. Moreover, the altered balance between the binding of the 
adenine/nicotinamide portions of the coenzyme determines a large drop in AIF-
G307E ability to discriminate between NADH and NADPH. 
 
Keywords: Neurodegeneration, flavoprotein, protein-ligand interaction, charge-
transfer complex 
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The apoptosis inducing factor (AIF) [1, 2] is a mitochondrial flavoprotein, 
highly conserved in vertebrates and with homologs in most eukaryotes [2, 3]. It is 
encoded by the AIFM1 gene on the X chromosome and translated as a precursor 
apoprotein with an N-terminal mitochondrial localization sequence (MLS) and two 
nuclear localization signals (NLS) [4]. The mature form of the protein, AIF1-54, is 
tethered to the intermembrane side of mitochondrial inner membrane via its N-
terminal segment [1]. As other mitochondrial proteins, AIF has a role in programmed 
cell death, being the main mediator of caspase-independent apoptosis [1, 2]. 
Apoptotic stimuli can produce the soluble AIF1-102 form, which is released into the 
cytosol [5, 6] and, if translocated into the nucleus, can bind DNA to promote 
chromatin condensation and large-scale DNA degradation [7]. However, AIF is also 
critical for the integrity of mitochondria in healthy cells [5, 8, 9]. Down-regulation of 
AIFM1 expression impairs oxidative phosphorylation (OXPHOS), mainly affecting 
complexes I and III [5, 10], suggesting that AIF has a function in respiratory chain 
biogenesis and/or maintenance [2]. This hypothesis is supported by the recent 
discovery that AIF is required for the translation-coupled import and activity of 
CHCHD4 [11], an intermembrane mitochondrial space protein that participates to the 
oxidative folding of respiratory complexes subunits [12].  
Most of the molecular mechanism by which AIF assists mitochondrial 
structure and functions still remains elusive. However, AIF interaction with NAD(H) 
seems to be pivotal for the vital functions of the flavoprotein [2, 13]. NAD(H)-
binding to AIF yields an exceptionally oxygen-stable FADH--NAD+ charge-transfer 
complex (AIFCT) that leads to large conformational rearrangements and dimerization 
of the protein [13-15]. These features led to the hypothesis that AIF could represent a 
redox and/or NADH sensor, taking part to a novel signal-transduction pathway [2, 
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13]. Moreover, AIFCT formation and protein dimerization are known to prevent its 
nuclear localization, to weaken its interaction with DNA and to hamper interactions 
with pro-survival cytoplasmatic partners [13]. 
OXPHOS defects are typically associated with neurodegeneration [16]. Both 
the Harlequin mouse, a natural murine strain where AIF level is decreased by 80%, 
and experimental models of AIF deficiency display OXPHOS defects, mitochondrial 
alterations and neuron loss [2, 9]. To date, nineteen human pathogenic AIF allelic 
variants have been identified, eleven of which associated with auditory neuropathy 
spectrum disorders [17], and the others causing neurodegenerative diseases of 
different degrees of severity [18-25]. Among the latter group, we focused our 
attention on the G308E replacement, responsible of a rare mitochondrial 
encephalopathy [19]. We have recently reported the thorough biochemical 
characterization of murine AIF-G307E, equivalent to human AIF-G308E, 
demonstrating that this replacement selectively slows down the rate of AIFCT 
formation [26]. The effect of the amino acid replacement on the reaction between the 
AIF variant harboring oxidized FAD (AIF-G307EOX) and NADH was particularly 
dramatic, indicating strong destabilization of the initial complex [26]. Our results 
were fully confirmed by a similar study carried out on the human AIF-G308E variant 
[27], thus supporting the concept that the mouse homolog is an excellent model of 
human AIF. While only the crystal structure of the oxidized form of the human AIF-
G308E variant has been reported so far [27], we succeeded in determining that of 
murine AIF-G307ECT, the first CT complex of a pathogenic AIF variant, here 
described in comparison with the respective oxidized form. We also report new 
relevant details of the effects of the G307E replacement on the catalytic properties of 
AIF, which prove that the conformational alterations observed in the crystal are 
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maintained in solution. These new findings provide a comprehensive picture of the 
impact of the G307E replacement on the reactivity of AIF towards nicotinamide 
ligands.  
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Materials and Methods 
Expression and purification of AIF forms. Mouse wild type AIF1-101 and its 
G307E variant were produced and purified as already described [26]. Purified 
proteins were stored at -80 °C in 50 mM Tris-HCl (pH 7.4), 10% glycerol, and their 
concentration was determined spectrophotometrically using an 452 of 12.8 mM–1cm-1. 
Crystallization and crystal data collection. Before crystallization trials, 
dimeric AIF-G307ECT was generated mixing 250 µM (14 mg/mL) oxidized protein 
with 2.5 mM NADH for 3 h at 0 °C in 100 mM bis-tris propane (pH 7.4). The 
complex was then isolated by gel filtration on a Superdex 200 column (GE 
Healthcare) and concentrated to about 12 mg/mL. 1 mM NADH was then added to 
avoid CT complex reoxidation during crystal growth. Crystals of AIF-G307EOX and 
AIF-G307ECT were grown at 20 °C in vapour-diffusion set up (Oryx-8 crystallization 
robot; Douglas Instruments, East Garston, UK) from a 2:1 mixture of protein and 
reservoir solution (drop volume 0.3 µL). Crystals of AIF-G307EOX were obtained 
after one day of vapour diffusion against 30% PEG 4000 and 0.2 M sodium acetate 
(pH 8.5). Crystals of AIF-G307ECT were obtained after one day of vapour diffusion 
against 10% PEG 6000, 0.1 M HEPES (pH 7.0). 
Before data collection, crystals were soaked in cryoprotectant solution 
containing 20% glycerol and flash-frozen in liquid nitrogen. The X-ray diffraction 
data were collected at the ESRF beamline ID29 (Grenoble, France) and were indexed 
and scaled using XDS [28] to a resolution of 3.5 Å and 3.1 Å for the oxidized and 
reduced forms, respectively.  
Structure solution and refinement. The structures of AIF-G307EOX and AIF-
G307ECT were solved by the molecular replacement method using the program 
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MOLREP [29] and the corresponding structures of wild type murine AIF (PDB-ID: 
3GD3 and 3GD4, respectively) [14] as search models. For both crystals, the two 
molecules in the crystal asymmetric unit were subjected to rigid-body refinement, and 
subsequently to constrained refinement using REFMAC5 [30]. A random set 
comprising 5% of the data was omitted from refinement for R-free calculation. 
Manual rebuilding with COOT [31] and additional refinement with BUSTER [32] and 
REFMAC5 [30] were performed as needed. Buried surface areas and contacts 
between domains were calculated using PISA [33]. Crystal parameters and data 
collection statistics for both AIF-G307EOX and AIF-G307ECT are summarized in 
Table 1. Atomic coordinates and structure factors for the oxidized and CT complex 
states of AIF-G307E have been deposited in PDB [34], with accession codes 5MIU 
and 5MIV, respectively. PyMol Graphic System (Schrödinger, LLC) was used for 
figures preparation. 
Kinetic studies. All kinetic measurements were performed using either an 8453 
diode-array (Agilent) or an SF-61 DX2 diode-array stopped-flow (HiTech) 
spectrophotometer. The NADH- or NADPH-dependent 2,6-dichlorophenolindophenol 
(DCIP) reductase reactions catalyzed by wild type AIF or AIF-G307E were 
monitored under steady-state conditions at 25 °C in 50 mM Na-phosphate (pH 7.5). 
For kinetic parameters estimation, the concentration of nicotinamide dinucleotides 
was varied between 0.1 and 15 mM, while that of DCIP was kept constant at 30 µM. 
Data fitting was performed as previously reported [26]. The time course of CT 
complex formation between the AIF forms and NADH or NADPH was monitored 
after mixing the oxidized proteins with different concentrations of each nucleotide 
ligand at 25 °C in 50 mM Na-phosphate buffer (pH 7.5). To estimate the parameters 
of the process, the concentration of NADH or NADPH was varied between 0.02 and 
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15 mM. Absorbance traces at 450 and 700 nm (specific for AIF-bound oxidized FAD 
and CT complex, respectively) were fitted to a single exponential decay equation 
using the software KinetAsyst version 3.0 (Hi-Tech Scientific) to estimate the values 
of apparent first-order rate constants (k) of the processes [26]. 
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Results 
Crystal structures of AIF-G307E. Crystals of AIF-G307E in its oxidized and 
CT complex states both belonged to the orthorhombic space group P212121 with two 
molecules per asymmetric unit. As previously reported [35], the protein is composed 
of three domains: a FAD-binding domain (residues 122−262 and 400−477), a NADH-
binding domain (residues 263−399) and a C-terminal domain (478−610). Both the 
FAD- and NADH-binding domains display the classical Rossmann fold topology, 
whereas the C-terminal domain is composed of five antiparallel β-strands followed by 
two -helices. As in all AIF deposited PDB entries, only few electron density 
portions of the AIF-G307E regulatory peptide [2] (residues 508-558) are defined 
(AIF-G307EOX: residues 508-522; AIF-G307ECT: residues 508-509, 539-543, 557-
558). 
Structure of AIF-G307E in its oxidized state. The crystals of AIF-G307EOX 
diffracted to a maximum resolution of 3.5 Å, and the structure was refined to a final 
crystallographic R-factor of 21.0%, and R-free of 27.8% (Table 1). Structural 
superposition of the two independent protein C backbones of chain A and B (446 
amino acids) yields r.m.s.d. value of 0.5 Å. The superimposition of chain A of the 
AIF variant to murine wild type AIFOX (PDB code: 3GD3 [14], r.m.s.d. of 0.7 Å on 
453 C atoms; Figure 1) pointed out the same differences observed by Sevrioukova 
in the corresponding human mutant variant (PDB code: 5FS8) [27]. In particular, 
Glu307 lines the wall of the NADH-binding channel and is well ordered, but to 
accommodate its bulkier side chain, the nearby Glu335 rotates its 2 angle by ~180º. 
Furthermore, the steric hindrance of the mutated residue causes a ~0.8 Å shift of the 
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333-335 segment, which affects in cascade the positioning of the 365-370 and the 
379-387 portions of the protein. 
Structure of AIF-G307E in its CT complex with NAD+. The crystals of AIF-
G307ECT diffracted to a maximum resolution of 3.1 Å, and the structure was refined 
to a final crystallographic R-factor of 19.9%, and R-free of 25.9% (Table 1). As 
already described for wild type AIF [14], the two molecules in the asymmetric unit (A 
and C; Figure 2A) are closer than in the structure of oxidized AIF-G307E, thus 
engaging tighter interactions, the main of which are two intermolecular Glu412-
Arg448 salt bridges. Structural superimposition of the two protein C backbones (439 
amino acids) yields r.m.s.d. value of 0.2 Å. The superimposition of chain A of AIF-
G307ECT to murine wild type AIFCT (PDB code: 3GD4 [14]; r.m.s.d. of 1.1 Å) 
pointed out that all the NADH-driven conformational changes leading to dimeric CT 
complex formation [14, 15] are conserved in the mutant variant. Fourier maps, at 
various stages of the crystallographic refinement, revealed strong residual electron 
density compatible with the NAD+ molecule that was accordingly modeled (Figure 
2B-C). As in wild type AIFCT, the nicotinamide ring of the ligand is stacked between 
FAD isoalloxazine and Phe309 rings (Figure 2C). 
The G307E replacement mainly alters the position of the adenylate moiety of 
bound NAD+ causing its reorientation with a 2 Å shift (Figure 3A). In these 
conditions, a hydrogen bond between the side chain of Arg264 and NAD+ O2B is 
established through a water molecule (Figure 3B). The effect of the mutation also 
affects the protein portion surrounding the NAD+ adenylate moiety, as speculated by 
Sevrioukova [27]. Compared to AIF-G307EOX structure, a shift of the 332-335 
peptide is also observed in AIF-G307ECT, though with no consequences on Glu335 
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orientation. Nevertheless, such shift leads to the disengagement of Glu335 from its 
interaction with the adenosine ribose of NAD+ and to the establishment of a weak 
electrostatic interaction with the adenine ring (Figure 3B). Furthermore, the 
repositioning of NAD+ adenylate moiety causes the severing of the hydrogen bond 
between the dinucleotide pyrophosphate and Lys341 that becomes involved in a weak 
interaction with the adenosine ribose (Figure 3B). The complete comparison of the 
direct interactions between NAD+ and AIF in the wild type and G307E CT complexes 
is summarized in Table 2. Overall, the altered conformation of the physiological 
ligand explains the lower affinity of AIF-G307E for NAD(H) and the dramatic 
decrease of the rate for CT complex formation [26].  
Kinetic studies of AIF-G307E. We speculated that the perturbation of NAD(H) 
adenylate moiety binding, observed in AIF-G307ECT structure, might result in a 
decreased ability of the protein to discriminate between NAD(H) and NADP(H). 
Therefore, we studied the reactivity of both wild type and G307E AIF forms towards 
NADPH in steady-state and pre-steady state conditions. The Km
NADPH values of the 
NADPH-DCIP diaphorase reactions catalyzed by both wild type and G307E AIF 
forms were found so high that only the kcat/Km
NADPH parameter could be estimated 
with acceptable precision. The catalytic efficiency of both AIF forms towards 
NADPH was found much lower than that towards NADH (Table 3). Notably, while 
the G307E replacement decreases kcat/Km
NADH by a factor of 140, it reduces 
kcat/Km
NADPH only 20-fold. Therefore, the dinucleotide selectivity of AIF, measured as 
the ratio between kcat/Km
NADH and kcat/Km
NADPH, drops about 6-fold (from about 45 to 
7) as a consequence of the mutation. As shown in Table 3, such loss in specificity is 
also reflected by the kinetics of CT complex formation by reaction of AIF forms with 
NADH or NADPH. Indeed, the klim/K0.5 ratio of the various reactions closely 
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approximates the corresponding steady-state kcat/Km parameter, indicating that, while 
the reactivity of both AIF forms towards NADH is higher than that towards NADPH, 
the G307E mutation considerably attenuates such difference.   
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Discussion 
To date, nineteen pathogenic human AIF variants have been discovered, some 
of which still lack a biochemical characterization. Filling this gap of knowledge is 
particularly urgent, due to the increasing rate at which new disease-causing AIF 
variants are emerging. We undertook the detailed study of murine AIF-G307E, 
demonstrating that this mutation has the selective effect to dramatically decrease the 
rate of reaction between AIF and NAD(H), possibly due to the impairment of the 
flavoprotein interactions with the adenylate moiety of the ligand [26]. The new 
structural and functional findings, here reported, fully corroborate such hypothesis 
and complete the picture of the consequences of the pathogenic G307E replacement. 
With the aim to understand in detail the structural effects of the mutation, we 
obtained the crystal structure of mouse AIF-G307E in both its oxidized and CT 
complex states, at 3.5 Å and 3.1 Å resolution, respectively. Even though resolution 
was not particularly high, the main structural differences leading to the selective 
effects of the G307E change on protein-NAD+ interactions have been unambiguously 
observed. The structural analysis of AIF-G307ECT provides direct evidence that the 
mutation specifically affects the interaction of AIF with NAD+ adenylate moiety. In 
particular, the steric hindrance of Glu307 in the mutant variant causes a shift of the 
333-335 peptide and most importantly the different orientation of both Glu335 and 
Lys341 side chains. Glu335 and Lys341 are pivotal residues in AIF, being involved in 
important interactions with NAD+ [14], allowing its correct positioning and the 
stabilization of the CT complex. A reorientation of NAD+ adenylate moiety was 
observed in AIF-G307ECT, as a consequence of all these structural changes.  
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Since wild type AIF is known to display a significant preference for NADH 
over NADPH [2], we hypothesized that, by hampering the binding of the half of the 
ligand molecule that differentiates the two dinucleotides, the mutation could alter 
substrate selectivity of AIF. We thus analyzed the NADPH-dependent DCIP 
reductase activities of the wild type and G307E AIF forms. As expected, the wild type 
protein proved to possess a 45-fold higher specificity for NADH in respect to 
NADPH. This difference was reduced only to 7-fold for AIF-G307E, showing a much 
lower ability to discriminate between the two nicotinamide dinucleotides. Being CT 
complex formation the limiting step for AIF redox activity, similar results were 
obtained by the pre-steady state kinetic study of this pivotal process.  
These new structural and functional observations complete our previous 
thorough biochemical characterization of AIF-G307E [26]. The study here presented 
could help in paving the way for a full understanding of the vital role that AIF plays 
in mitochondria and for the future development of therapies to cure threatening 
diseases associated with its deficiency and/or malfunctioning. 
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Table 1. X-ray data-collection and refinement statistics.  
Data collection AIF-G307EOX AIF-G307ECT 
Beam line & 
wavelength (Å) 
ESRF ID29  
0.97895  
ESRF ID29  
0.97895 
Space group P212121 P212121 
Unit-cell parameters (Å) a=96.0; b=110.1; c=119.6 a=73.4; b=116.8; c=166.5 
Molecules in a.u. 2 2 
Resolution (Å) 48.7 – 3.5 43.5 – 3.1 
Unique reflections 16,448 (1,197)a 26,576 (1,946)b 
Completeness (%) 99.4 (99.8) 99.5 (99.8) 
Redundancy 5.4 (5.7) 4.5 (4.7) 
Rmeas† (%) 39.3 (129.5) 18.8 (127.8) 
CC(1/2) (%) 97.3 (73.5) 99.2 (33.1) 
Average I/σ (I) 5.3 (1.8) 6.6 (1.3) 
Final model   
R factor‡/Rfree§ (%) 21.0/27.8 19.9/25.9 
r.m.s. bonds (Å) 0.009 0.010 
r.m.s. angles (°) 1.31 1.52 
Average protein B fac. (Å2) 73.0 95.0 
Residues in most favored 
regions (%) 
94.5% 97.0% 
Residues in additionally 
allowed regions (%) 
5.4% 3.0% 
PDB-ID 5MIU 5MIV 
Values in parentheses are for the highest resolution shell: a(3.59-3.50), b(3.18-3.10). 
† Rmeas = (Σ (n/(n-1) Σ |I - (I)| )/ Σ I x 100, where I is intensity of a reflection and (I) is its average 
intensity.  
‡ Rfactor = Σ |Fo - Fc| / Σ |Fo| x 100.  
§ Rfree is calculated on 5% randomly selected reflections, for cross-validation. 
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Table 2. Distances of AIF-NAD+ direct interactions in the CT complexes engaged by 
the wild type and G307E protein forms. 
 AIFCT (PDB-ID: 3GD4 [14]) AIF-G307ECT (PDB-ID: 5MIV) 
Residue NAD+ atoms Mean (Å) a NAD+ atoms Mean (Å) a 
G307/E307 O2B 2.9 O4B 2.9 
F309 O2A, O1N 3.1, 3.2 -  
L310 O1N 3.2 O1N 2.8 
E313 N7N 2.8 N7N 2.9 
E335 O2B, O3B 2.8, 2.8 N3A 3.8 
K341 O1A 2.7 O2B 3.2 
A396 O4B, O2N 3.7, 3.3 -  
V397 -  N7A 3.5 
G398 O2N 2.8 O2N 3.0 
E452 O2D, O3D 2.6, 2.6 O2D, O3D 2.7, 2.6 
H453 O7N 2.8 O7N 2.9 
W482 N7N 2.6 N7N 3.0 
 
a Mean of the distances measured in the two molecules present in the asymmetric unit. 
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Table 3. Effect of the G307E replacement on the reactivity of AIF towards NADH and NADPH, as evaluated under steady-state and pre-steady 
state conditions.a 
 
 
 
 
 
 
 
aAll kinetic measurements were determined at 25 °C in 50 mM Na-phopshate (pH 7.5). 
bData taken from Sorrentino et al. (2015) [26] are shown here for comparison. 
cSteady-state kinetic parameters of the NADH/NADPH-DCIP diaphorase reaction catalyzed by AIF. 
dApparent second-order rate constant of CT complex formation by reaction of oxidized AIF forms with NADH or NADPH. 
  
AIF form 
NADHb  NADPH 
kcat
c Km
c kcat/Km
c klim/K0.5
d  kcat/Km
c klim/K0.5
d 
(s-1) (mM) (M-1s-1) (M-1s-1)  (M-1s-1) (M-1s-1) 
Wild type 1.38 ± 0.02 1.60 ± 0.08 860 ± 33 550 ± 28  19.0 ± 0.3 25.0 ± 2.2 
G307E 0.060 ± 0.001 8.5 ± 0.4 6.7 ± 0.2 7.6 ± 0.4  0.93 ± 0.02 0.90 ± 0.08 
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Figure Legends 
 
Figure 1. The G307E replacement causes local conformational changes in AIF-
G307EOX. The structure of AIF-G307E in its oxidized state is shown as magenta 
cartoons. The 333-336, 365-372, 378-389 peptides of the wild type and G307E AIF 
forms are shown in grey and cyan, respectively. Electron density for AIF-G307EOX 
333-336 segment is shown in cyan. Relevant elements are displayed as sticks: E307 is 
shown in magenta with dots highlighting the steric hindrance of its side chain; E335 is 
shown with grey and cyan carbon atoms, for the wild type and G307E AIF forms, 
respectively; FAD is shown with yellow carbon atoms. Nitrogen, phosphorus and 
oxygen atoms are shown in blue, orange and red, respectively. Arrows indicate the 
shifts caused by the G307E mutation. 
 
Figure 2. The dimeric CT complex of AIF-G307E. AIF-G307E dimer is shown in 
cartoon representation, with molecules A and C in magenta and pink, respectively. 
Relevant elements are displayed as sticks: FAD carbon atoms are shown in yellow 
while those of NAD+ and F309 in the color of the corresponding molecule. Nitrogen, 
phosphorus and oxygen atoms are shown in blue, orange and red, respectively. (A) 
The dimer formed by molecules A and C in the asymmetric unit. (B) Zoomed view in 
molecule A, where the green cage shows the Fo-Fc difference Fourier map calculated 
after few refinement cycles of the protein structure alone. (C) The AIF-G307E-NAD+ 
CT complex in molecule A. 
 
Figure 3. The G307E replacement alters NAD+ positioning in AIF. The structure 
of AIF-G307E in its CT complex with NAD+ is shown as magenta cartoons. Nitrogen, 
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phosphorus and oxygen atoms are shown in blue, orange and red, respectively. (A) 
The displacement of NAD+ adenylate moiety in AIF-G307E: FAD is shown in sticks 
with yellow carbon atoms; NAD+ is shown in sticks with grey and magenta carbon 
atoms in the wild type and G307E AIF-NAD+ CT complexes, respectively; E307 is 
shown in magenta sticks with the surface of its steric hindrance colored in magenta. 
(B) The interaction pattern of NAD+ in AIF-G307E: NAD+ in the mutant AIF variant 
is shown as in panel A; residues interacting with the ligand are shown with purple 
carbon atoms; the water molecule acting as a bridge between R264 and NAD+ O2B is 
shown as a light blue sphere; red and green dashed lines represent interactions that are 
altered or unaltered by the G307E mutation, respectively. 
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